t 47d 23 9  (ATCC)

Journal: Journal of medicinal chemistry

Article Title: Design of hydrazide-bearing HDACIs based on panobinostat and their p53 and FLT3-ITD dependency in anti-leukemia activity

doi: 10.1021/acs.jmedchem.0c00442

Figure Lengend Snippet: National Cancer Institute Developmental Therapeutics Program In Vitro Testing Results of 13a .

Article Snippet: Concentration response curves performed in triplicates were generated using GraphPad Prism software. table ft1 table-wrap mode="anchored" t5 Table 5. caption a7 Cancer Types Cell Line GI 50 (nM) LC 50 (nM) Leukemia CCRF-CEM 40.6 >10,000 HL-60 34.2 >10,000 K-562 35.2 >10,000 MOLT-4 47.7 >10,000 RPMI-8226 26.8 >10,000 SR 94.7 >10,000 Non-Small Cell Lung Cancer A549/ATCC 176 >10,000 EKVX 285 >10,000 HOP-62 102 >10,000 HOP-92 23.0 >10,000 NCI-H226 52.3 460 NCI-H23 182 >10,000 NCI-H322M 173 >10,000 NCI-H460 163 >10,000 NCI-H522 96.9 >10,000 Colon Cancer COLO 205 29.8 660 HCC-2998 143 1760 HCT-116 22.9 879 HCT-15 313 >10,000 HT29 32.4 >10,000 KM12 116 >10,000 SW-620 53.0 >10,000 CNS Cancer SF-268 198 >10,000 SF-295 131 >10,000 SF-539 98.9 >10,000 SNB-19 231 >10,000 SNB-75 312 >10,000 U251 80.1 4280 Melanoma LOX IMVI 118 537 MALME-3M 48.2 >10,000 M14 72.5 >10,000 MDA-MB-435 97.5 >10,000 SK-MEL-2 73.9 >10,000 SK-MEL-28 68.7 893 SK-MEL-5 192 >10,000 UACC-257 79.6 >10,000 UACC-62 72.6 589 Ovarian Cancer IGROV1 115 >10,000 OVCAR-3 135 >10,000 OVCAR-4 105 >10,000 OVCAR-5 31.6 >10,000 OVCAR-8 41.3 >10,000 NCI/ADR-RES 516 >10,000 SK-OV-3 98.3 >10,000 Renal Cancer 786–0 161 >10,000 ACHN 85.5 >10,000 CAKI-1 101 4300 RXF 393 23.4 666 SN12C 158 >10,000 TK-10 17.3 >10,000 UO-31 173 >10,000 Prostate Cancer PC-3 54.2 >10,000 DU-145 90.8 >10,000 Breast Cancer MCF7 106 >10,000 MDA-MB-231/ATCC 203 >10,000 HS 578T 121 >10,000 BT-549 338 >10,000 T-47D 23.9 >10,000 MDA-MB-468 50.4 >10,000 Open in a separate window National Cancer Institute Developmental Therapeutics Program In Vitro Testing Results of 13a .

Techniques: In Vitro